Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Calvin Trieu

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Alzheimer'S Research & Therapy|February 6, 2026
Real-world diagnostic performance of blood-based biomarkers for Alzheimer's disease: robust performance except after stroke and high charlson comorbidity indexSinthujah Vigneswaran, Inge M W Verberk, Rebecca Z Rousset, et al.
JAMA Network Open|July 10, 2025
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical SpectrumDiederick M de Leeuw, Calvin Trieu, Ellen M Vromen, et al.
Frontiers in Psychiatry|June 25, 2025
Longitudinal associations between amyloid and symptoms of depression and anxiety in subjective cognitive decline: the impact of personality characteristicsCalvin Trieu, Mardou S S A van Leeuwenstijn, Lisa-Marie Schlüter, et al.
Journal of Alzheimer'S Disease : JAD|March 15, 2024
Alzheimer's Disease and Cognitive Decline in Patients with Cardiovascular Diseases Along the Heart-Brain AxisCalvin Trieu, Argonde C van Harten, Anna E Leeuwis, et al.
Neurology|June 1, 2026
Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired IndividualsCalvin Trieu, Ellen Dicks, Diederick de Leeuw, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 1, 2024
Amyloid PET disclosure in subjective cognitive decline: Patient experiences over timeHeleen M A Hendriksen, Tanja J de Rijke, Agnetha Fruijtier, et al.
Patient Education and Counseling|February 2, 2025
Needs expressed by people with subjective cognitive decline during amyloid PET disclosure consultations: An observational studyTanja J de Rijke, Heleen M A Hendriksen, Agnetha D Fruijtier, et al.
Alzheimer'S Research & Therapy|March 28, 2026
Longterm impact of disclosing amyloid PET results to individuals with subjective cognitive declineJetske van der Schaar, Wiesje M van der Flier, Leonie N C Visser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2023
Contributions of amyloid beta and cerebral small vessel disease in clinical declineJustine E F Moonen, Renée Haan, Isabelle Bos, et al.
Alzheimer'S Research & Therapy|December 3, 2025
Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderlyMadison I J Honey, Ingrid S van Maurik, Argonde C van Harten, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Alzheimer'S Research & Therapy|February 6, 2026
Real-world diagnostic performance of blood-based biomarkers for Alzheimer's disease: robust performance except after stroke and high charlson comorbidity indexSinthujah Vigneswaran, Inge M W Verberk, Rebecca Z Rousset, et al.
JAMA Network Open|July 10, 2025
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical SpectrumDiederick M de Leeuw, Calvin Trieu, Ellen M Vromen, et al.
Frontiers in Psychiatry|June 25, 2025
Longitudinal associations between amyloid and symptoms of depression and anxiety in subjective cognitive decline: the impact of personality characteristicsCalvin Trieu, Mardou S S A van Leeuwenstijn, Lisa-Marie Schlüter, et al.
Journal of Alzheimer'S Disease : JAD|March 15, 2024
Alzheimer's Disease and Cognitive Decline in Patients with Cardiovascular Diseases Along the Heart-Brain AxisCalvin Trieu, Argonde C van Harten, Anna E Leeuwis, et al.
Neurology|June 1, 2026
Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired IndividualsCalvin Trieu, Ellen Dicks, Diederick de Leeuw, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 1, 2024
Amyloid PET disclosure in subjective cognitive decline: Patient experiences over timeHeleen M A Hendriksen, Tanja J de Rijke, Agnetha Fruijtier, et al.
Patient Education and Counseling|February 2, 2025
Needs expressed by people with subjective cognitive decline during amyloid PET disclosure consultations: An observational studyTanja J de Rijke, Heleen M A Hendriksen, Agnetha D Fruijtier, et al.
Alzheimer'S Research & Therapy|March 28, 2026
Longterm impact of disclosing amyloid PET results to individuals with subjective cognitive declineJetske van der Schaar, Wiesje M van der Flier, Leonie N C Visser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2023
Contributions of amyloid beta and cerebral small vessel disease in clinical declineJustine E F Moonen, Renée Haan, Isabelle Bos, et al.
Alzheimer'S Research & Therapy|December 3, 2025
Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderlyMadison I J Honey, Ingrid S van Maurik, Argonde C van Harten, et al.
Pageof 3